Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp ndovascular therapy (EVT) is a minimally invasive treatment modality for patients with peripheral artery disease (PAD) and it has been established as the first-line therapy for revascularization of PAD patients compared with surgical bypass. 1,2 However, the femoropopliteal (FP) region still remains a challenge for EVT. Although the initial success rate of EVT for FP lesions had been reported as 95% for stenoses and more than 85% even for occlusive lesions, the long-term patency of superficial femoral artery (SFA) lesions is far from satisfactory after EVT. 2 Compared with traditional balloon angioplasty, nitinol stent implantation in the SFA might achieve more favorable patency. 3,4 In fact, there is increasing evidence that the advantage of nitinol stenting over angioplasty increases as the lesion becomes longer. Although the FAST trial, in which short lesions (average legion length 45 mm) were studied, didn't prove the superiority of the nitinol stent to angioplasty alone, 5 the ASTRON (average legion length 84 mm) and ABSOLUTE (average legion length 130 mm) trials, when a longer lesion compared with that in the FAST trial was treated, showed that the advantage of stenting is greater. 3,6 However, a comparison of long-term patency beyond a 1 year between 2 different nitinol stents has not been performed systematically. Therefore, we compared the long-term patency of 2 different nitinol stents, the S. Shinsuke Nanto, MD, PhD; Seiki Nagata, MD, PhD
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USA), in propensity matched patients who were followed for up to 5 years.
Methods

Patients
We retrospectively analyzed a multicenter, prospectively maintained database from April 2004 to December 2008 that included 638 limbs from the 511 consecutive patients who successfully underwent EVT for de novo SFA lesions with nitinol stent implantation, and who also gave consent to a follow-up ultrasound and X-ray examination at the Kansai Rosai Hospital Cardiovascular Center, the Cardiology Department of Kokura Memorial Hospital and the Cardiology Department of Saiseikai Yokohama Eastern Hospital. During this observation period, the 3 centers managed 1,382 consecutive patients (1,899 limbs) who underwent EVT for SFA. All of the patients had symptomatic SFA lesions (Rutherford 2-6) that affected their quality of life in spite of exercise and optimal medications. We excluded patients who underwent angioplasty alone, those who underwent stenting for restenosis, and those presenting with acute or subacute limb ischemia. We also excluded patients who were not followed for at least 6 months without an end-point (restenosis, amputation, or death). Fifty-four limbs of 38 patients who received nitinol stent implantation for SFA lesions were excluded because we could not follow them up beyond 6 months. The study protocol was designed in accordance with the Declaration of Helsinki, and it was approved by the ethics committee of each hospital. This study was registered with the University Hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR), which is accepted by the International Committee of Medical Journal Editors (no. UMIN000002726, REAL-SL registry: REtrospective multicentre AnaLysis of S.M.A.R.T. and Luminexx nitinol stent implantation for SFA). All of the patients gave written informed consent.
Protocol
After initial diagnostic angiography of the lower limb, the indications for EVT were decided after consulting vascular surgeons. The indication for EVT of SFA lesions was >70% diameter stenosis without inflow lesions. The approach for EVT was determined at the operator's discretion. In general, after a 6F sheath was inserted, either a 0.035-or a 0.014-inch wire was advanced into the lesion, and unfractionated heparin (5,000 units) was injected into the artery. The lesion was expanded for 60 s with an optimal balloon. In accordance with the ACC/AHA guidelines, a stent was implanted in patients with a residual peak pressure gradient >10 mmHg, residual stenosis >30%, and/or flow-limiting dissection following balloon dilatation. 
Follow-up and Outcomes
Clinical evaluation that included symptoms, the ankle-brachial index, lesion patency on ultrasound, and stent fracture on X-ray was performed at baseline, 24 and 72 h after the procedure, after 1 month, and then every 3 months. Primary patency was defined as a peak systolic velocity ratio <2.4 on duplex ultrasound. 7 Stent fracture was defined as a definite break (>1-2 mm) in the stent struts identified by X-ray in 4 projections associated with kinking or misalignment of the stent in the axial direction. At each follow-up examination, an X-ray was done in 4 projections to detect stent fracture, which was evaluated by 2 observers who had experienced more than 1,000 EVT cases. Bent knee radiography was not performed. The primary end-point of this study was the comparison of primary patency between the 2 types of nitinol stent after follow up for as long as 5 years.
Statistical Analysis
All statistical analyses were performed with SAS 6.10 software (SAS Institute, Cary, NC, USA). Continuous variables are presented as the mean ± standard deviation and were compared by the unpaired t-test. In the S.M.A.R.T. stent and Luminexx stent groups, the primary end-point was examined by the Kaplan-Meier method and the groups were compared with the log-rank test. Prognostic variables for end-points were investigated by Cox univariate analysis, while a multivariate Cox regression model was used to determine predictors of the end-points. Factors that were indicated by a P<0.2 on univariate Cox analysis were entered into the multivariate regression models. To minimize the differences between the 2 stent groups and better assess the effect of the stent itself, we also performed propensity-matched analysis. Based on a multivariate logistic regression model, each patient was assigned a propensity score. Convariates entered into the model included: gender, age, female gender, diabetes, hypertension, hyperlipidemia critical limb ischemia, TASC C and D, lesion length, Infrapopliteal run-off, number of stents used, lesion calcification and administration of cilostazol. The area under the receiver operating characteristics curve was drawn for stent use and the propensity score was 0.62. Patients in the S.M.A.R.T. group and those in the Luminexx group were matched 1:1 on the basis of their estimated propensity scores.
Freedom from restenosis and clinical events were then analyzed in the propensity matched groups. In all analyses, P<0.05 was considered statistically significant.
Results
Patients, Lesion Characteristics and Procedures
The patients, lesion characteristics, and EVT procedures are summarized in Table 1 . A total of 638 limbs from 511 con- 
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secutive patients underwent nitinol stent implantation for de novo SFA lesions. The mean age was 72±9 years and 72% were male. Sixty-two percent of the patients had diabetes mellitus and 21% had end-stage renal disease on dialysis. The average lesion length was 159±89 mm and 47% of the lesions were TASC C/D. Stent fracture was observed in 14% of the limbs. S.M.A.R.T. stents were deployed for 79% of the lesions. Sixty-four percent of the patients were administered cilostazol.
Comparison of the S.M.A.R.T. and Luninexx Stent Groups
A comparison of characteristics between the S.M.A.R.T. stent group and the Luninexx stent group is shown in Table 1 . There were no statistical differences between the 2 groups in terms of patient characteristics and lower limb characteristics, except that hypertension was more frequent in the S.M.A.R.T. stent group than the Luninexx stent group. Regarding lesion characteristics, the lesion length was longer (154±93 mm vs. 135±71 mm, P=0.03) and the chronic total occlusion lesion was more prevalent (55% vs. 40%, P=0.002) in the S.M.A.R.T. stent group than in the Luninexx stent group. Accordingly, the number of stents used per vessel was higher in the S.M.A.R.T. stent group than in the Luninexx stent group (1.8±0.9 vs. 1.6±0.8, P=0.0048). However, the incidence of stent fracture was higher in the Luninexx stent group than in the S.M.A.R.T. stent group (23% vs. 11%, P= 0.0005). Administration of cilostazol was more frequent in the S.M.A.R.T. stent group than in the Luninexx stent group (68% vs. 48%, P<0.0001).
Comparison Between S.M.A.R.T. and Luminexx Stents for Primary Patency
A comparison of primary patency between the S.M.A.R.T. stent group and the Luminexx stent group is shown in Figure 1 . After the first year, the patency rate of S.M.A.R.T. stents tended to be better compared with that of Luninexx stents (81% vs. 75%, P=0.07). However, there were no significant differences in terms of long-term patency between the S.M.A.R.T. and Luninexx stents after follow up for as long as 5 years (66% vs. 64% at 5 years, P=0.50).
Comparison Between S.M.A.R.T. and Luminexx Stents for Primary Patency With and Without Stent Fracture
A comparison of primary patency with and without stent fracture between S.M.A.R.T. and Luminexx stents is shown in Figure 2 . Primary patency was worse in those associated with stent fracture than in those without stent fractures during the chronic phase in each nitinol stent (S.M.A.R.T. stent: 56% with fracture vs. 67% without fracture, P=0.023; Luminexx stent: 49% with fracture vs. 69% without fracture, P=0.015), but it was not significantly different between the 2 types of nitinol stents without stent fracture (S.M.A.R.T. stent 67% vs. Luminexx stent 69% at 5 years, P=0.731).
Comparison Between S.M.A.R.T. and Luninexx Stents for Primary Patency After Propensity-Matching Analysis
A comparison of primary patency between the S.M.A.R.T. and Luninexx stents in the propensity matched subgroup is shown in Figure 3 . This analysis also showed no significant differences of long-term patency between the S.M.A.R.T. stent and Luninexx stent for up to 5 years (74% vs. 65% at 5 years, P=0.10). 
Discussion
By monitoring 1,149 stents implanted in 638 limbs with SFA lesions, we compared the long-term patency of 2 different nitinol stents in this study. Although different stent fracture rates were observed over the long term, there was no significant difference of primary patency between the S.M.A.R.T. and Luninexx stent groups when follow up was continued for as long as 5 years.
PAD has been estimated to affect more than 10 million people in the United States 8, 9 and also has been increasing in Asia. 10 PAD is a multilevel disease involving the FPA lesion in more than 50% of cases. 11 Although conventional balloon angioplasty has been the standard therapy for FPA lesions, it has also been associated with a low primary patency rate and the resultant frequent need for repetitive revascularization. 1,2 There is increasing evidence that the primary patency rate achieved with nitinol stents is superior to that of early metallic stents, 12-15 as well as that after balloon angioplasty alone. 4, 6 However, a comparison of the long-term patency of 2 different nitinol stents beyond 1 year has not been performed so far. The Super SL study involved the comparison of the restenosis rate between the S.M.A.R.T. stent (n=96) and the Luminexx stent (n=103) in patients with SFA lesions after 1 year. It was reported that the 12-month restenosis rate judged by duplex sonography was 34.8% in the S.M.A.R.T. stent group and 44.2% in the Luninexx stent group. Similar to our results, that study did not demonstrate the superiority of a 1-year patency for the S.M.A.R.T. stent compared with the Luminexx stent. 16, 17 However, there are few reports on the patency of nitinol stents over longer periods, and to the best Stent fracture is an important issue after implantation of nitinol stents in the SFA. It is considered to be a risk factor for in-stent restenosis and re-occlusion in the chronic phase after SFA stenting, 18 just as it has been suggested to be a cause of coronary restenosis. 19 Although there was no significant difference in terms of long-term patency between the S.M.A.R.T. stent and the Luminexx stent in patients followed for as long as 5 years, the primary patency rate of the S.M.A.R.T. stent was better compared with that of the Luminexx stent at 1 year (81% vs. 75% at 5 years, P=0.07). Differences in the structure of the segments and the number of connecting bridges between these 2 stents might be related to the differences of the stent fracture rate and patency at 1 year. However, the primary patency ratio in both of the 2 groups was relatively higher than those reported by others. 16, 18 We speculate that a low stent fracture ratio compared with earlier studies and administration of cilostazol contributed to a better outcome during the chronic phase. A low stent fracture rate might be attributed to the differences in lifestyle and physic in the East.
Study Limitations
This was a retrospective and non-randomized study, despite using a prospectively maintained database and propensitymatched analysis. Also, the number of patients followed in the chronic phase was relatively small. Although the standard error was less than 10% during the 5 years, this study might lack statistical power to confirm the difference between the 2 types of nitinol stent. Further investigation of new-generation stents is needed in the near future.
Conclusion
Although a difference of the stent fracture rate was observed in the chronic phase, there was no significant difference in terms of primary patency between the S.M.A.R.T. stent and the Luninexx stent in patients followed up for as long as 5 years.
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